GT Biopharma, Inc. | Business Contracts

Settlement and Investment Agreement dated August 24, 2022, by and between GT Biopharma, Inc. and Cytovance Biologics, Inc (Filed With SEC on October 31, 2022)

Employment Agreement with Manu Ohri dated May 15, 2022 (Filed With SEC on May 16, 2022)

Sublease Agreement dated November, 2021, between Aimmune Therapeutics, Inc. (Sublandlord) and GT Biopharma, Inc. (Subtenant) (Filed With SEC on March 28, 2022)

Research Agreement with Regents of the University of Minnesota, dated June 16, 2021 (Filed With SEC on March 28, 2022)

Exclusive License Agreement with Regents of the University of Minnesota, dated March 26, 2021 (Filed With SEC on March 28, 2022)

Certificate of Designation of Preferences, Rights and Limitations of Series K Preferred Stock of GT Biopharma, Inc., dated April 3, 2019 (Filed With SEC on April 16, 2021)

Board Service Agreement with Michael Breen dated November 11, 2020 (Filed With SEC on May 16, 2022)

Employment Agreement with Michael Breen, entered into as of December 31, 2021 with an effective date of November 8, 2021 (Filed With SEC on March 28, 2022)

Amended and Restated Employment Agreement with Anthony Cataldo, dated April 23, 2021 (Filed With SEC on May 17, 2021)

Amended and Restated Employment Agreement with Dr. Gregory Berk, dated April 23, 2021 (Filed With SEC on May 17, 2021)

Amended and Restated Employment Agreement with Michael Handelman, dated April 23, 2021 (Filed With SEC on May 17, 2021)

Form of December 2020 / January 2021 Note (Filed With SEC on February 9, 2021)

Form of Securities Purchase Agreement (Filed With SEC on February 9, 2021)

Amendment to Convertible Note, effective as of January 31, 2021, by and between GT Biopharma, Inc. and Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (Filed With SEC on February 9, 2021)

Board Service Agreement with Michael Breen, dated January 12, 2021 (Filed With SEC on February 8, 2021)

Form of Underwriting Agreement (Filed With SEC on February 8, 2021)

Board Service Agreement with Rajesh Shrotriya, dated January 12, 2021 (Filed With SEC on February 8, 2021)

Form of December 2020 / January 2021 Note (Filed With SEC on February 8, 2021)

Amendment to Settlement Note with Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B (Filed With SEC on February 8, 2021)

Form of Securities Purchase Agreement - December 2020 / January 2021 Notes (Filed With SEC on February 8, 2021)

Form of Pre-Funded Warrant (Filed With SEC on February 2, 2021)

Form of Warrant (Filed With SEC on February 2, 2021)

Form of Amendment to Convertible Note, dated as of January 31, 2021 (Filed With SEC on February 2, 2021)

Form of Second Amendment and Extension of Standstill and Forbearance Agreement (Filed With SEC on February 2, 2021)

CONVERTIBLE NOTE DUE JANUARY 31, 2021 (Filed With SEC on December 28, 2020)

SETTLEMENTAGREEMENT (Filed With SEC on December 28, 2020)

AMENDMENT TO CONVERTIBLE NOTE & STANDSTILLAGREEMENT (Filed With SEC on December 23, 2020)

Steve Weldon Letter of Resignation, dated November 11, 2020 (Filed With SEC on November 13, 2020)

Consultant Agreement with Michael Handelman, dated November 13, 2020 (Filed With SEC on November 13, 2020)

Board Service Agreement with Greg Berk, dated November 11, 2020 (Filed With SEC on November 13, 2020)

Board Service Agreement with Bruce Wendel, dated November 11, 2020 (Filed With SEC on November 13, 2020)

Form of Settlement Note, dated November 9, 2020 (Filed With SEC on November 13, 2020)

Settlement Agreement, dated as of November 9, 2020, by and among Adam Kasower, East Ventures, Inc., A British Virgin Islands company, SV Booth Investments III, LLC, a Delaware... (Filed With SEC on November 13, 2020)

Securities Purchase Agreement (Filed With SEC on November 9, 2020)

Form of Secured Convertible Note (Filed With SEC on November 9, 2020)

Master Services Agreement (Filed With SEC on October 6, 2020)

Form of Secured Convertible Note (Filed With SEC on September 22, 2020)

Securities Purchase Agreement (Filed With SEC on September 22, 2020)

Employment agreement with Anthony Cataldo (Filed With SEC on August 14, 2020)

Employment agreement with Steven Weldon (Filed With SEC on August 14, 2020)

Form of Secured Convertible Note (Filed With SEC on July 9, 2020)

Securities Purchase Agreement (Filed With SEC on July 9, 2020)

Registration Rights Agreement (Filed With SEC on July 9, 2020)

STANDSTILL AND FORBEARANCE AGREEMENT (Filed With SEC on June 23, 2020)

Form of Pre-Funded Warrant to Purchase Common Stock, dated June 19, 2020 (included in Exhibit 10.1) (Filed With SEC on June 19, 2020)

Form of Convertible Note, dated June 19, 2020 (included in Exhibit 10.1) (Filed With SEC on June 19, 2020)

Settlement Agreement, dated as of June 19, 2020, among GT Biopharma, Inc., Empery Asset Master Ltd., Empery Tax Efficient, LP and Empery Tax Efficient II, LP, Anthony Cataldo and... (Filed With SEC on June 19, 2020)

Securities Purchase Agreement by and among the Company and the Buyers, dated January 30, 2020 (Filed With SEC on May 15, 2020)

Securities Purchase Agreement by and among the Company and the Buyers, dated April/May, 2020 (Filed With SEC on May 15, 2020)

Form of Note, dated April/May, 2020 (Filed With SEC on May 15, 2020)

Form of Registration Rights Agreement by and among the Company and the Buyers, dated January 30, 2020 (Filed With SEC on May 15, 2020)

Form of Note, dated January 30, 2020 (Filed With SEC on May 15, 2020)

Form of Registration Rights Agreement by and among the Company and the Buyers, dated April/May, 2020 (Filed With SEC on May 15, 2020)

Clinical Trial Agreement with University of Minnesota (Filed With SEC on May 15, 2020)

Registration Rights Agreement (Filed With SEC on August 23, 2019)

Securities Purchase Agreement (Filed With SEC on August 23, 2019)

Form of Secured Convertible Note (Filed With SEC on August 23, 2019)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on May 24, 2019)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on May 24, 2019)

CONVERTIBLE NOTE DUE NOVEMBER ___, 2019 (Filed With SEC on May 24, 2019)

Security Agreement by and among the Company, Alpha Capital Anstalt, as collateral agent, and the Purchasers, dated February 4, 2019 (Filed With SEC on February 6, 2019)

Securities Purchase Agreement by and among the Company and the Purchasers, dated February 4, 2019 (Filed With SEC on February 6, 2019)

Registration Rights Agreement by and among the Company and the Purchasers, dated February 4, 2019 (Filed With SEC on February 6, 2019)

Form of Secured Convertible Note, dated February 4, 2019 (Filed With SEC on February 6, 2019)

GT Biopharma, Inc. (64)